Production & Sales - Launches

Mayne Pharma launches Lexette (halobetasol propionate) foam 0.05% in US

Mayne Pharma Group, a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, has launched LEXETTE (halobetasol propionate) Foam 0.05% in the US.

GSK, Kyowa Hakko Kirin to commercialize anemia drug daprodustat in Japan

British drugmaker GlaxoSmithKline (GSK) has entered into a collaboration with Kyowa Hakko Kirin to commercialize daprodustat in Japan.

Nexus Pharmaceuticals gets FDA nod for Arsenic Trioxide injection in 10mg per 10mL vial

Nexus Pharmaceuticals has announced the immediate availability of Arsenic Trioxide Injection in 10mg per 10mL vial in the US.

Ferring launches Nocdurna in US to treat nocturia due to NP

Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.

GW announces US launch of cannabinoid medicine for seizures

GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.

Cipher launches Brinavess antiarrhythmic drug in Canada

Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.

Alliance Pharma launches nausea drug Xonvea in UK

Alliance Pharma has launched Xonvea, a new prescription drug for the treatment of nausea and vomiting of pregnancy (NVP), in the UK.

Gilead to launch generic versions of hepatitis C drugs in US

Gilead Sciences is planning to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) in the US.

US hospital groups establish not-for-profit generic drug company

Civica Rx, the initiative earlier known as Project Rx, is the name of a new not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving medications.